A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Chromosome Analysis,Amniotic Fluid Reflex to ClariSure®,Oligo-SNP,Prenatal
Test CodeCHFLA
Alias/See Also
92704
CPT Codes
88235, 88269, 88280
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Includes
If Chromosomes Analysis, Amniotic Fluid is normal, then the Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP will be performed at an additional charge. (CPT code(s): 81229).
Preferred Specimen
30 mL fresh amniotic fluid collected in a sterile tube
Minimum Volume
10 mL
Instructions
Patient's age, gestational age, and indication(s) for testing are necessary; please submit completed cytogenetics requisition form with information. Do not split even if AFP requested. Send all tubes to lab (supernatant for AFP will be split by cytogenetics lab).
**Signed informed consent is a requirement. Amniotic fluid kit and handling instruction available upon request.
This test may be replaced by other Bill Codes, if the complete study cannot be performed, or if the specimen does not yield mitotically active cells for analysis: Prenatal Specimen Culture; or Cytogenetics Communication (if a communication is required).
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not reject.
**Signed informed consent is a requirement. Amniotic fluid kit and handling instruction available upon request.
This test may be replaced by other Bill Codes, if the complete study cannot be performed, or if the specimen does not yield mitotically active cells for analysis: Prenatal Specimen Culture; or Cytogenetics Communication (if a communication is required).
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Preferred
Refrigerated: Acceptable
Frozen: Unacceptable
Refrigerated: Acceptable
Frozen: Unacceptable
Methodology
Culture • Karyotype • Microscopy
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 6-8 days after receipt at the performing laboratory, additional days for reflex if needed. Add two (2) additional days for transport.
Reference Range
See Laboratory Report
Clinical Significance
Testing determines chromosomal status of the fetus. Numerical and structural chromosomal abnormalities can be diagnosed. Sex and the presence of more than one cell line (mosaicism) can also be determined. Indications include diagnosis of chromosome abnormalities in fetuses of women who are of advanced maternal age; had a previous child with a chromosome abnormality; parental carrier of a balanced translocation, inversion or marker chromosome; parental mosaicism and follow-up for abnormal maternal serum alpha fetoprotein or maternal screening results.
Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP - This assay may be useful for:
• Further investigation on fetuses with abnormal ultrasound findings indicating congenital malformation.
• Further definition of an imbalanced cytogenetic abnormality.
• Further investigation on equivocal cytogenetic findings.
• Attempt at characterization of supernumerary marker chromosome.
• Follow-up to a documented chromosome abnormality or genomic alteration in a sibling or a parent.
• Family history of a previous child with mental retardation and/or phenotypic abnormalities.
Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP - This assay may be useful for:
• Further investigation on fetuses with abnormal ultrasound findings indicating congenital malformation.
• Further definition of an imbalanced cytogenetic abnormality.
• Further investigation on equivocal cytogenetic findings.
• Attempt at characterization of supernumerary marker chromosome.
• Follow-up to a documented chromosome abnormality or genomic alteration in a sibling or a parent.
• Family history of a previous child with mental retardation and/or phenotypic abnormalities.
Performing Laboratory
Quest Diagnostics Nichols Institute |
14225 Newbrook Drive |
Chantilly, VA 20153 |
Last Updated: May 5, 2023